EP1175418A2 - Nouvel agent pharmaceutique - Google Patents

Nouvel agent pharmaceutique

Info

Publication number
EP1175418A2
EP1175418A2 EP00922793A EP00922793A EP1175418A2 EP 1175418 A2 EP1175418 A2 EP 1175418A2 EP 00922793 A EP00922793 A EP 00922793A EP 00922793 A EP00922793 A EP 00922793A EP 1175418 A2 EP1175418 A2 EP 1175418A2
Authority
EP
European Patent Office
Prior art keywords
polymoφh
diabetes mellitus
provides
compound
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00922793A
Other languages
German (de)
English (en)
Inventor
Paul David James SmithKline Beecham Blackler
Robert Gordon SmithKline Beecham GILES
Stephen SmithKline Beecham MOORE
Michael John SmithKline Beecham SASSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909471.6A external-priority patent/GB9909471D0/en
Priority claimed from GBGB9912195.6A external-priority patent/GB9912195D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to EP02080319A priority Critical patent/EP1277753A1/fr
Publication of EP1175418A2 publication Critical patent/EP1175418A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • WO99/31094 and WO99/31095 each disclose distinct hydrates of Compound (I). It has now been discovered that Compound (I) exists in a novel polymorphic form which is particularly suitable for bulk preparation and handling. The novel form can be prepared by an efficient, economic and reproducible process particularly suited to large-scale preparation.
  • the novel polymorphic form ('the Polymorph') also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. Accordingly, the present invention provides a polymorphic form of 5-[4-[2-
  • the Polymorph provides an infrared spectrum substantially in accordance with Figure I .
  • the Polymorph provides a Raman spectrum substantially in accordance with Figure II.
  • the Polymorph provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I. In one favoured aspect, the Polymorph provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.
  • XRPD X-ray powder diffraction
  • the present invention encompasses the Polymorph isolated in pure form or when admixed with other materials, for example the known forms of Compound I or any other material.
  • the Polymorph in crystalline form in yet a further aspect there is provided the Polymorph in crystalline form.
  • the invention also provides a process for preparing the Polymorph, characterised in that a solution of Compound (I) in denatured ethanol at an elevated temperature, preferably in the range of from 65 °C to 70 °C for example 67.5 °C, is cooled preferably to a temperature in the range of from 20 °C to 25°C, so as to provide crystallisation of the Polymorph.
  • the solution is filtered prior to cooling.
  • the solution may be seeded with the Polymorph to induce crystallisation but this is not essential.
  • the Polymorph is then recovered from the denatured ethanol.
  • the solution of Compound (I) in the denatured ethanol is conveniently prepared by dissolving Compound (I) in the required amount of denatured ethanol at an elevated temperature, for example 60°C or 70°C.
  • the Polymorph is recovered from the denatured ethanol by filtration and subsequent drying.
  • the invention provides a process for converting Polymorph to Compound (I), wherein a solution of Polymorph in a suitable solvent, such as acetone or ethanol, is seeded with Compound (I); preferably the reaction is carried out in an inert atmosphere, such as nitrogen.
  • a suitable solvent such as acetone or ethanol
  • the reaction is carried out in an inert atmosphere, such as nitrogen.
  • the solution of Polymorph is obtained by dissolving Polymorph at an elevated temperature in the solvent, such as acetone or ethanol.
  • Compound (I) refers to the form of5-[4-[2-(N-memyl-N-(2-pyridyl)ammo)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt as disclosed an characterised in International Patent Application, Publication Number WO94/05659.
  • denatured ethanol means ethanol containing small amounts of methanol, usually up to 5% v/v of methanol, such as from 0.9% v/v to 5% v/v of methanol, for example ethanol containing 4%v/v of methanol.
  • the term 'prophylaxis of conditions associated with diabetes mellitus' includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.
  • Diabetes mellitus preferably means Type II diabetes mellitus.
  • Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity.
  • Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis, certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia.
  • Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.
  • the complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
  • the compound of the invention has useful therapeutic properties:
  • the present invention accordingly the Polymorph for use as an active therapeutic substance.
  • the present invention provides the Polymorph for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
  • the Polymorph may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the formulation of the Polymorph and dosages thereof are generally as disclosed for Compound (I) in International Patent Application, Publication Number WO94/05659 or WO98/55122.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the Polymorph and a pharmaceutically acceptable carrier therefor.
  • the Polymorph is normally administered in unit dosage form.
  • the active compound may be administered by any suitable route but usually by the oral or parenteral routes.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
  • compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl g-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
  • fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
  • compositions may contain further active agents such as anti-hypertensive agents and diuretics.
  • the Polymorph may be used in combination with other antidiabetic agents such as insulin secretagogues, for example sulphonylureas, biguanides, such as metformin, alpha glucosidase inhibitors, such as acarbose, beta agonists, and insulin such as those disclosed in WO98/57649, WO98/57634, WO98/57635 or WO98/57636.
  • insulin secretagogues for example sulphonylureas, biguanides, such as metformin, alpha glucosidase inhibitors, such as acarbose, beta agonists, and insulin such as those disclosed in WO98/57649, WO98/57634, WO98/57635 or WO98/57636.
  • the other antidiabetic agents, the amounts thereof and methods of administration are as described in the above mentioned publications.
  • the formulation of the Polymorph and dosages thereof in said combinations are generally as disclosed for Compound (I) in
  • the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • the present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the Polymorph to a human or non-human mammal in need thereof.
  • the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
  • the present invention provides the use of the Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof. No adverse toxicological effects are indicated in the above mentioned treatments for the compounds of the invention.
  • a mixture of maleic acid (2.10 g) and 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione (6.0 g) were heated to 70°C in denatured ethanol (60 ml, 5%v/v methanol) until complete dissolution was obtained.
  • the resultant solution was filtered, re-heated to 67.5°C, and then cooled to 20-25°C.
  • the resulting crystalline product was filtered off, washed with denatured ethanol (10 ml) and dried at 50°C in vacuo to give the Polymorph (6.61 g, 83%).
  • Peak positions are as follows 1752, 1709, 1642, 1613, 1576, 1546, 1514, 1412, 1359, 1329, 1317, 1291, 1261, 1242, 1220, 1212, 1204, 1182, 1171, 1154, 1126, 1112, 1097, 1075, 1056, 1032, 1016, 966, 937, 918, 906, 861, 842, 821, 809, 792, 762, 743, 715, 665, 656, 650, 621, 602, 560, 541, 524 and 507 c ⁇ r 1 .
  • the Raman spectrum of the Polymo ⁇ h was recorded through a glass vial using a Perkin Elmer 2000R spectrometer at 4 cm" 1 resolution and is shown in Figure II (X-axis shows Intensity, Y-axis shows Raman shift cm” 1 , 1800 - 200 cm - 1 ). Excitation was achieved using a Nd:YAG laser (1064 nm) with a power output of 400 mW.
  • Peak positions are as follows: 1751, 1683, 1614, 1586, 1547, 1468, 1449, 1382, 1344, 1317, 1243, 1211, 1181, 1150, 1076, 1016, 991, 918, 841, 825, 773, 742, 652, 637, 619, 602, 512, 470, 428, 406, 350 and 325 cm" 1 .
  • the XRPD pattern of the Polymo ⁇ h is shown below in Figure IV and a summary of the XRPD angles and calculated lattice spacings characteristic of the Polymo ⁇ h is given in Table II.
  • Data were acquired on a Bruker D8 Advance X-ray diffractometer with theta/theta geometry configured with a Cu anode, primary and secondary Soller slits, a secondary monochromator, and scintillation detector. The following acquisition conditions were used:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Forme polymorphe de 5-[4-[2-(N-méthyle-N-(2-pyridyl)amino)éthoxy]benzyl]thiazolidine-2,4-dione, sel d'acide maléique (le « polymorphe ») caractérisée par le fait qu'elle produit : (i) un spectre infrarouge contenant des crêtes à 1752, 1546, 1154, 621 et 602 cm-1; et/ou (ii) un spectre de Raman contenant des crêtes à 1751, 1243 et 602 cm-1; et/ou (iii) un spectre de résonance magnétique nucléaire par semi-conducteur contenant des crêtes à 111,9, 114,8, 119,6, 129,2, 134, 138, 144,7, 153,2, 157,1, 170,7, 172 et 175 ppm ; et/ou (iv) une configuration de diffraction de poudre aux rayons X (XRPD) produisant des espacements de réseau calculés de 6,46, 5,39, 4,83, 4,68, 3,71, 3,63, 3,58 et 3,48 Angströms ; procédé servant à préparer ce composé, composition pharmaceutique contenant ce composé et son utilisation médicale.
EP00922793A 1999-04-23 2000-04-19 Nouvel agent pharmaceutique Withdrawn EP1175418A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02080319A EP1277753A1 (fr) 1999-04-23 2000-04-19 Dérivé de thiazolidinedione et son utilisation comme antidiabétique

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9909471.6A GB9909471D0 (en) 1999-04-23 1999-04-23 Novel compounds
GB9909471 1999-04-23
GB9912195 1999-05-25
GBGB9912195.6A GB9912195D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical
PCT/GB2000/001522 WO2000064893A2 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP02080319A Division EP1277753A1 (fr) 1999-04-23 2000-04-19 Dérivé de thiazolidinedione et son utilisation comme antidiabétique

Publications (1)

Publication Number Publication Date
EP1175418A2 true EP1175418A2 (fr) 2002-01-30

Family

ID=26315459

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00922793A Withdrawn EP1175418A2 (fr) 1999-04-23 2000-04-19 Nouvel agent pharmaceutique
EP02080319A Withdrawn EP1277753A1 (fr) 1999-04-23 2000-04-19 Dérivé de thiazolidinedione et son utilisation comme antidiabétique

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02080319A Withdrawn EP1277753A1 (fr) 1999-04-23 2000-04-19 Dérivé de thiazolidinedione et son utilisation comme antidiabétique

Country Status (36)

Country Link
EP (2) EP1175418A2 (fr)
JP (1) JP2002543076A (fr)
KR (1) KR100744361B1 (fr)
CN (1) CN1152878C (fr)
AP (1) AP1607A (fr)
AR (2) AR023560A1 (fr)
AU (2) AU4307200A (fr)
BG (1) BG65517B1 (fr)
BR (1) BR0009935A (fr)
CA (1) CA2370262A1 (fr)
CO (1) CO5170419A1 (fr)
CZ (1) CZ20013801A3 (fr)
DZ (1) DZ3164A1 (fr)
EA (1) EA003031B1 (fr)
EG (1) EG23937A (fr)
GC (1) GC0000250A (fr)
HK (1) HK1045152A1 (fr)
HR (1) HRP20010774A2 (fr)
HU (1) HUP0200937A3 (fr)
IL (1) IL146115A0 (fr)
MA (1) MA26786A1 (fr)
MX (1) MXPA01010822A (fr)
MY (1) MY138673A (fr)
NO (1) NO320587B1 (fr)
NZ (1) NZ515167A (fr)
OA (1) OA11873A (fr)
PE (1) PE20010045A1 (fr)
PL (1) PL351685A1 (fr)
SK (1) SK14932001A3 (fr)
TR (1) TR200103060T2 (fr)
TW (1) TWI288749B (fr)
UA (1) UA67845C2 (fr)
UY (1) UY26119A1 (fr)
WO (1) WO2000064893A2 (fr)
YU (1) YU75401A (fr)
ZA (1) ZA200108718B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
EP1690940A1 (fr) * 1999-04-13 2006-08-16 The Government of the United States of America as Represented by The Department of Health and Human Services Production de vaccins à base d'un virus respiratoire syncytial chimérique attenue à partir de séquences nucléotidiques clonées
PL351684A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Polymorph of 5−[4−[2− (n−methyl−n−( 2−pyridyl)amino) ethoxy]benzyl] thiazolidine−2,4−dione, maleic acid salt
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2004062667A1 (fr) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Forme amorphe du maleate de rosiglitazone et procede de preparation
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (fr) * 2003-04-18 2004-11-03 CHEMI S.p.A. Formes polymorphes de maléate de rosiglitatone
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
TW201336497A (zh) * 2007-02-08 2013-09-16 Daiichi Sankyo Co Ltd 噻唑啶二酮化合物之結晶型及其製法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0064893A2 *

Also Published As

Publication number Publication date
OA11873A (en) 2006-03-27
EG23937A (en) 2008-01-14
HUP0200937A2 (en) 2002-08-28
YU75401A (sh) 2004-09-03
KR100744361B1 (ko) 2007-07-30
AU2755102A (en) 2002-05-16
MXPA01010822A (es) 2002-06-04
EA003031B1 (ru) 2002-12-26
CA2370262A1 (fr) 2000-11-02
IL146115A0 (en) 2002-07-25
HRP20010774A2 (en) 2002-10-31
BG106122A (en) 2002-05-31
AP2001002329A0 (en) 2001-12-31
EP1277753A1 (fr) 2003-01-22
HK1045152A1 (zh) 2002-11-15
JP2002543076A (ja) 2002-12-17
PE20010045A1 (es) 2001-03-10
CO5170419A1 (es) 2002-06-27
MY138673A (en) 2009-07-31
TR200103060T2 (tr) 2002-05-21
AU4307200A (en) 2000-11-10
BR0009935A (pt) 2002-04-16
TWI288749B (en) 2007-10-21
KR20010110804A (ko) 2001-12-13
WO2000064893A2 (fr) 2000-11-02
CN1152878C (zh) 2004-06-09
MA26786A1 (fr) 2004-12-20
SK14932001A3 (sk) 2002-02-05
CN1355800A (zh) 2002-06-26
DZ3164A1 (fr) 2000-11-02
NO320587B1 (no) 2005-12-27
WO2000064893A3 (fr) 2001-01-25
HUP0200937A3 (en) 2004-03-29
NZ515167A (en) 2004-02-27
UY26119A1 (es) 2000-12-29
ZA200108718B (en) 2002-12-03
BG65517B1 (bg) 2008-10-31
AR023750A1 (es) 2002-09-04
PL351685A1 (en) 2003-06-02
NO20015148L (no) 2001-12-17
AR023560A1 (es) 2002-09-04
GC0000250A (en) 2006-11-01
NO20015148D0 (no) 2001-10-22
AP1607A (en) 2006-05-03
AU771342B2 (en) 2004-03-18
UA67845C2 (uk) 2004-07-15
CZ20013801A3 (cs) 2002-07-17
EA200101122A1 (ru) 2002-04-25

Similar Documents

Publication Publication Date Title
EP1173435B1 (fr) Nouvelle forme polymorphe du sel d'acide 5- 4- 2- (n-methyl-n-( 2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione,maleique
EP1173434B1 (fr) Derive du thiazolindione et son utilisation comme antidiabetique
EP1042321A1 (fr) Derive substitue de la thiazolidinedione son procede de preparation et ses emplois en pharmacie
AU771342B2 (en) Novel pharmaceutical
EP1661895A1 (fr) Produit pharmaceutique constitue par un hydrate, sel de l'acide maleique, de 5-[ 4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione
US7230109B2 (en) 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
WO2000063205A2 (fr) Nouveau compose pharmaceutique
ZA200108722B (en) Thiazolidinedione derivative and its use as antidiabetic.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011031

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011031;LT PAYMENT 20011031;LV PAYMENT 20011031;MK PAYMENT 20011031;RO PAYMENT 20011031;SI PAYMENT 20011031

17Q First examination report despatched

Effective date: 20020213

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041118

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1045152

Country of ref document: HK